sábado, 16 de julio de 2022

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial - The Lancet Respiratory Medicine

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial - The Lancet Respiratory Medicine

No hay comentarios:

Publicar un comentario